Nu-Med Plus FCF per Share
Free Cash Flow per Share of Nu-Med Plus (NUMD) as of Nov 3, 2026.
Get this data via API
Financial Data API
FCF per Share
-0.00USD
YoY
982.31%
Last updated:
Free Cash Flow per Share of Nu-Med Plus is 2025 -0.00 USD. Free Cash Flow per Share of Nu-Med Plus was 2024 -0.00 USD. It decreases by 982.31% lower compared to the previous year.
The Nu-Med Plus FCF per Share history
3 Years
10 Years
25 Years
Max
FCF per Share
Date
FCF per Share
Jan 1, 2018
-0.01 USD
Jan 1, 2019
-0.01 USD
Jan 1, 2020
-0.01 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.00 USD
Jan 1, 2023
-0.00 USD
Jan 1, 2024
-0.00 USD
Jan 1, 2025
-0.00 USD
| YEAR | FCF per Share | YoY |
|---|---|---|
| -0.00USD | +982.31% | |
| -0.00USD | -93.32% | |
| -0.00USD | +67.99% | |
| -0.00USD | -81.85% | |
| -0.00USD | -67.93% | |
| -0.01USD | -36.27% | |
| -0.01USD | +11.41% | |
| -0.01USD | -100.16% | |
| 7.33USD | +191.91% | |
| 2.51USD | +6.55% | |
| 2.36USD | -55,659.18% | |
| -0.00USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Nu-Med Plus Stock analysis
What does Nu-Med Plus do? Nu-Med Plus Inc is a US company specializing in the development of medical devices and technologies. The company was founded in 2011 by Cameron Wakefield and is headquartered in Salt Lake City, Utah.
Nu-Med Plus' business model is based on the development of innovative solutions for healthcare and medical equipment. The company focuses mainly on the development of medical gases and specifically nitric oxide technologies.
As a leader in nitric oxide technology, Nu-Med Plus offers a variety of products. These include devices for the administration of nitric oxide, such as the Nu-Med Plus Nitric Oxide Delivery System, which allows for precise dosage of nitric oxide.
In addition, the company has also developed a range of products based on the use of nitric oxide. These include nasal sprays for the treatment of angina and other heart conditions, as well as inhalable medications for the treatment of acute asthma.
However, Nu-Med Plus is not only specialized in nitric oxide technologies. The company has also developed devices and technologies targeting other areas of healthcare.
These products include the Nu-Med Plus Portable Oxygen Concentrator, a portable oxygen concentrator system, and the Nu-Med Plus Wireless Vital Sign Monitoring System, a wireless technology for real-time monitoring of patients' vital signs.
Furthermore, Nu-Med Plus has formed partnerships with other companies in the medical industry, allowing the company to expand its range of products and services and enhance its commitment to medical research and development.
In the fiscal year 2020, Nu-Med Plus generated approximately $2.7 million in revenue and employed about 15 employees. With the increasing need for innovative medical solutions and the growing demand for medical gases and nitric oxide technologies, the company remains optimistic about its ability to continue its growth in the coming years.
Overall, Nu-Med Plus is a leading company in the field of medical devices and technologies. With its innovative research and development and strong partnerships, the company offers a wide range of products that can contribute to improving the quality of healthcare and making the lives of patients around the world easier. Nu-Med Plus is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Nu-Med Plus stock
On Eulerpool you can find the complete historical development of Free Cash Flow per Share Nu-Med Plus since 2006 – with annual values, charts, and detailed analysis.
FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Nu-Med Plus
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Nu-Med Plus
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth